Bavarian Nordic AS's lead investigational product, the prostate cancer vaccine Prostvac (rilimogene galvacirepvec), has failed at the Phase III stage, sending the firm's share price down by more than 48% to DKK228.5 on Sept. 15, and raising concerns over potential implications for another of its candidate vaccines.
The PROSPECT study's independent data monitoring committee has deemed continuing with the trial in metastatic castration-resistant prostate cancer futile, based...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

